Viking Therapeutics, Inc. (VKTX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß).
Is Viking Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of November 3, 2026, Viking Therapeutics, Inc. (VKTX) trades at $26.09 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Viking Therapeutics, Inc.
Market cap $3B · 52 weeks $24 – $42 (36 % below the high) · P/E no earnings · Dividend none · Next earnings February 10, 2027 · expected EPS -$1.34 · Closing price, Nov 3 · accounts published Oct 28.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 1 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 4.2×, fails.
- Cash Runway 30 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $2.47, info.
Against its peers (reference peers) — Viking Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -76.9 %; $3.3B. Acadia Pharmaceuticals Inc. (P/E 9.3×; EV/EBITDA 27.7×; ROIC 6.2 %; $3.5B), Telix Pharmaceuticals Limited (P/E 94.8×; EV/EBITDA 113×; ROIC -0.6 %; $3.1B), Nurix Therapeutics, Inc. (P/E 11.2×; EV/EBITDA 6.7×; ROIC 25.9 %; $2.8B).
Profitability
| Return on Equity | -117.35% |
| Return on Invested Capital | -76.91% |
| Return on Assets | -64.19% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.43 |
| Current Ratio | 7.27 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 28.62 |
Price Performance
| 1 month | -8.37% |
| 3 months | -19.43% |
| Year-to-date | -23.74% |
| 1 year | -22.52% |
| 3 years | +154.31% |
| 5 years | +310.87% |
| 10 years | +2637.76% |
Related companies: MDGL · NAMS · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of VKTX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks